Immunotherapy of cancer is now an essential pillar of treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration of new treatment strategies incorporating immune agents in cancer clinical practice. Immunotherapies perturb a complex system of interactions among genomically unstable tumor cells, diverse cells within the tumor microenvironment including the systemic adaptive and innate immune cells. The drive to develop increasingly effective immunotherapy regimens is tempered by the risk of immune-related adverse events. Evidence-based biomarkers that measure the potential for therapeutic response and/or toxicity are critical to guide optimal patient care and contextualize the results of immunotherapy clinical trials. Responding to the lack of guidance on biomarker testing in early-phase immunotherapy clinical trials, we propose a definition and listing of essential biomarkers recommended for inclusion in all such protocols. These recommendations are based on consensus provided by the Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) faculty with input from the SITC Pathology and Biomarker Committees and the Journal for ImmunoTherapy of Cancer readership. A consensus-based selection of essential biomarkers was conducted using a Delphi survey of SCION faculty. Regular updates to these recommendations are planned. The inaugural list of essential biomarkers includes complete blood count with differential to generate a neutrophil-to-lymphocyte ratio or systemic immune-inflammation index, serum lactate dehydrogenase and albumin, programmed death-ligand 1 immunohistochemistry, microsatellite stability assessment, and tumor mutational burden. Inclusion of these biomarkers across early-phase immunotherapy clinical trials will capture variation among trials, provide deeper insight into the novel and established therapies, and support improved patient selection and stratification for later-phase clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/jitc-2024-010928 | DOI Listing |
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891540 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Background: The development of immunotherapy has led to a paradigm shift in the treatment of malignant tumors. Immune checkpoint inhibitors (ICIs) function by blocking the receptors and ligands of T cells from binding one another, empowering them to target and attack cancer cells. ICIs along with other immunotherapy treatments, have seen a significant increase in usage in recent years.
View Article and Find Full Text PDFSurvival benefits of postoperative radiotherapy in esophageal cancer during the immunotherapy era:a retrospective cohort study based on the SEER database and a single-center registry in China.
Front Immunol
March 2025
Thoracic Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, China.
Purpose: The aim of this study was to investigate the survival benefits of postoperative radiotherapy (PORT) in patients with resectable esophageal cancer (EC) after neoadjuvant therapy in the Immunotherapy era.
Methods: The study was designed as a retrospective cohort study, which included a total of 733 patients with EC from the SEER database and a single-center cohort. We used propensity score matching (PSM) to equilibrate patient characteristics.
Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products.
Front Immunol
March 2025
Changchun University of Chinese Medicine, Changchun, China.
In recent years, tumor immunotherapy has made significant breakthroughs in the treatment of malignant tumors. However, individual differences in efficacy have been observed in clinical practice. There is increasing evidence that gut microbial metabolites influence the efficacy of distal tumor immunotherapy via the gut-liver axis, the gut-brain axis and the gut-breast axis, a process that may involve modulating the expression of immune cells and cytokines in the tumor microenvironment (TME).
View Article and Find Full Text PDFIdentification and functional characterization of T-cell exhaustion-associated lncRNA AL031775.1 in osteosarcoma: a novel therapeutic target.
Front Immunol
March 2025
Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Background: Osteosarcoma, an aggressive bone malignancy predominantly affecting children and adolescents, presents significant therapeutic challenges with a 5-year survival rate below 30% in metastatic cases. T-cell exhaustion, characterized by the overexpression of immune checkpoint molecules, contributes to osteosarcoma progression and immune evasion. Although targeting these inhibitory pathways has shown potential in restoring T-cell activity, the molecular regulators of T-cell depletion in osteosarcoma are poorly understood.
View Article and Find Full Text PDFIntegrated multiomics analysis and machine learning refine neutrophil extracellular trap-related molecular subtypes and prognostic models for acute myeloid leukemia.
Front Immunol
March 2025
Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Background: Neutrophil extracellular traps (NETs) play pivotal roles in various pathological processes. The formation of NETs is impaired in acute myeloid leukemia (AML), which can result in immunodeficiency and increased susceptibility to infection.
Methods: The gene set variation analysis (GSVA) algorithm was employed for the calculation of NET score, while the consensus clustering algorithm was utilized to identify molecular subtypes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!